,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04']
destiny-breast04: trastuzumab deruxtecan resulted in significantly longer pfs and os than the physician s choice of chemotherapy in pts with her-2 low metastatic breast cancer #asco22 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own